Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H18ClN3O5S
CAS Number:
Molecular Weight:
435.88
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Product Name
Rivaroxaban, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -34 to -44, c = 0.3 in DMSO
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[s]1c(ccc1C(=O)NC[C@@H]2OC(=O)N(C2)c3ccc(cc3)N4CCOCC4=O)Cl
InChI
1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
InChI key
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Biochem/physiol Actions
Rivaroxaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (IC50 = 0.7 nM; no activity against thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, or activated protein C up to 20 μM) with good anticoagulant activity in vitro (dose for doubling fibrin formation time = 230/300 nM in human/rat plasma) and antithrombotic efficacy in vivo (ED50 = 1 mg/kg i.v. or 5 mg/kg p.o. by rat arteriovenous shunt model).
Still not finding the right product?
Explore all of our products under Rivaroxaban
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 2
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
C Weinz et al.
Xenobiotica; the fate of foreign compounds in biological systems, 35(9), 891-910 (2005-11-26)
The pharmacokinetics of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - were investigated in rats and dogs in support of preclinical safety studies and clinical development. BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute
Georges Jourdi et al.
Thrombosis research, 183, 159-162 (2019-11-05)
Clinical benefit-risk balance of direct oral anticoagulants (DOAC) in atherothrombosis prevention differs between anti-Xa and anti-IIa drugs and their specific effect on platelet functions remains controversial. We hence investigated rivaroxaban and dabigatran effect on platelets in identical experimental conditions. Blood
Bart J Biemond et al.
Thrombosis and haemostasis, 97(3), 471-477 (2007-03-06)
Current anticoagulant therapies for the prevention and treatment of thromboembolic disorders have many drawbacks: vitamin K antagonists interact with food and drugs and require frequent laboratory monitoring, and heparins require parenteral administration. Oral rivaroxaban (BAY 597939) is a new, highly
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2844-25MG | 04061842334551 |
| SML2844-5MG | 04061842334568 |
